

19.01.00

PCT/NL 99/00782



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

NL 99/782

4

Bescheinigung      Certificate

Attestation

REC'D 17 FEB 2000

WIPO      PCT

09/869067

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr.   Patent application No.   Demande de brevet n°

98204370.5

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)


Der Präsident des Europäischen Patentamts:  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE  
07/01/00





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.:  
Demande n°:

98204370.5

Anmeldetag:  
Date of filing:  
Date de dépôt:

22/12/98

Anmelder:  
Applicant(s):  
Demandeur(s):  
DSM N.V.  
6411 TE Heerlen  
NETHERLANDS

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:

Process for the preparation of optically active alpha-aminonitriles

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:


Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:  
C12P13/00, C12P41/00, C12N9/80

Am Anmeldetag benannte Vertragstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques: The original title of the application reads as follows : Process for the preparation of alpha-aminonitriles with enhanced optical purity



- 1 -

PE 9872

5 PROCESS FOR THE PREPARATION OF  $\alpha$ -AMINONITRILES  
WITH ENHANCED OPTICAL PURITY

The invention relates to a process for the preparation of an  $\alpha$ -aminonitrile with enhanced optical purity wherein a mixture of the enantiomers of the N-formyl- $\alpha$ -aminonitrile is brought into contact with an acylase, whereby one of the enantiomers of the N-formyl  $\alpha$ -aminonitrile is selectively deformylated into the unprotected corresponding  $\alpha$ -aminonitrile.

15 There are no processes known in the art wherein a mixture of the enantiomers of an  $\alpha$ -aminonitrile is enzymatically, enantioselectively formylated, or wherein a mixture of the enantiomers of an N-formyl- $\alpha$ -aminonitrile is deformylated.

20 Applicant now has found that it is possible to remove the N-protecting formyl group enantioselectively from one of the enantiomers of a mixture of the enantiomers of N-formyl- $\alpha$ -aminonitriles. In such enantioselective processes moreover very high E-values can be obtained.

25  $\alpha$ -Aminonitriles to be used as a substrate in the process of the invention are for instance aliphatic and aromatic  $\alpha$ -aminonitriles, for example the  $\alpha$ -aminonitriles derived from phenylglycine, phenylalanine, m-methoxy-phenylalanine, valine and  $\alpha$ -methyl-phenylglycine. In the framework of this 30 invention an  $\alpha$ -aminonitrile is understood to be an  $\alpha$ -aminoacid wherein the carboxy group is replaced by a cyano group.

35 In another embodiment of the present invention a mixture of the enantiomers of a

- 2 -

(non-protected)  $\alpha$ -aminonitrile is subjected to a formylation in the presence of an acylase and a formylating agent, whereby one of the enantiomers is selectively converted into the corresponding N-formyl  $\alpha$ -aminonitrile.

Suitable formylating agents are for instance formic acid in case a thermodynamically controlled formylation can be performed, or formic acid esters or amides when the formylation is kinetically controlled. In a thermodynamically controlled formylation the equilibrium is shifted towards the side of the formyl derivative, preferably by precipitation of the formyl derivative.

Moreover it appeared that, starting from  $\alpha$ -aminonitriles, the non-formylated  $\alpha$ -aminonitriles relatively rapidly racemise at pH values of higher than 5. In such case the optically active N-formyl aminonitrile can be obtained with an enantiomeric excess of more than 90%, in particular more than 95% and with a yield of more than 90%, in particular more than 95%, calculated with respect to the total amount of (racemic)  $\alpha$ -aminonitrile starting product.

Suitable acylases that can be used in the process of the present invention are for instance Penicilline acylases for instance Pen-G or Pen-V acylases, metalloproteases, esterases, deacetylases. Particularly useful enzymes are peptide deformylases.

Peptide deformylases (PDF's) are in general enzymes having formyl methionine peptide deformylase activity. It should be noticed that in the literature also other names are being used instead of the name peptide deformylases; in particular the following names may be mentioned here: formylmethionine deformylase, N-formylmethionylaminoacyl-tRNA deformylase, N-formyl-L-

- 3 -

methionine amidohydrolase, N-formylmethionyl-aminoacyl-tRNA amidohydrolase.

Suitable peptide deformylases to be used in the process according to the invention are peptide deformylases classified as EC 3.5.1.27. Preferably, the enzyme is an enzyme having the activity as described for EC 3.5.1.27 because excellent results are being achieved in the deformylation with such enzymes. It should be noticed that until recently it was believed that the enzyme coded as EC 3.5.1.31 is catalyzing a different reaction. In the meantime, however, it has been shown that the enzymes known as EC 3.5.1.27 and EC 3.5.1.31 are coded for by exactly the same gene and have the same activity. Therefore, as used herein, the term EC 3.5.1.27 is encompassing not only EC 3.5.1.31, but likewise all other enzymes having the same activity as described for EC 3.5.1.27.

Although the family of PDF's is composed of proteins with a relatively low level of sequence identity, the 3D structures of the members of this family appear closely related one to each other with, in particular, the building of a common fold around the bivalent metal ion and three signature sequences. As is described (for PDF's indicated as PDF) by Wagner et al., J. Biol. Chem., 273, 11413-6 (1998), for many of these enzymes characteristically three short amino acid stretches are present as strictly conserved motifs, namely in that the enzymes contain the sequences (i) HEXXXH, (ii) EGCLS and (iii) GXGXAAQ. In these sequences X represents any natural amino acid, and standard one letter codes for amino acids are used: A = alanine, C = cysteine, E = glutamic acid, G = glycine, H = histidine, L = leucine, S = serine and Q = glutamine.

Peptide deformylases are obtainable for instance from eubacteria for example *Escherichia coli*, *Bacillus subtilis*, *Clostridium acetobutylicum*,

- 4 -

*Clostridium beijerinckii*, *Haemophilus influenzae*, *Thermotoga maritima*, *Thermus aquaticus*, *Thermus thermophilus*, *Calothrix PCC 7601*, *Bacillus stearothermophilus*, or *Lactococcus lactis*. Preferably 5 an enzyme obtainable from *Escherichia coli* is used.

Preferably a peptide deformylase is used with a bivalent metal ion whereby the metal is chosen from the groups 5-11 of the periodic system (New IUPAC version; see *Handbook of Chemistry and Physics* 70th 10 edition, CRC Press, 1989-1990, inner page of cover), as a cofactor. Preferably the metal is chosen from the group of V, Cr, Fe, Ni, Mn, Co, Cu, Pd and Pt, in particular from the group of Fe, Ni, Mn and Co, most preferably Fe or Ni.

15 Preferably the amount of the bivalent metal ions should be about equivalent to the number of moles of enzyme. Suitably the molar ratio between these bivalent metal ions and the number of PDF molecules is in the range of 0.6 to 1.4, preferably of 0.8 to 1.2, 20 and most preferred the amount of bivalent metal ions is equimolar to the enzyme.

Exchange of the bivalent metal ions in the PDF's in order to obtain PDF enzymes with a co-factor as necessary for the present invention can be done by 25 the various methods as described in Groche et al., *Biochem. Biophys. Res. Comm.*, 246, 342-346, (1998). These methods include simple metal displacement by incubation of the native enzyme in an excess of the desired bivalent metal ion, if necessary preceded by 30 the preparation of the apoenzyme via treatment of the native enzyme with a metal chelation compound. Furthermore, the desired bivalent metal ion can already

- 5 -

be introduced in (at least part of the enzyme molecules) by using a bacterial growth medium with an enhanced ratio of the desired bivalent metal ion over  $Fe^{2+}$ .

5 In addition measures may be taken in order to enhance the stability of the enzyme, for instance the addition of stabilisation agents, for instance catalase, tris-(2-carboxyethyl)phosphine, glucose oxidase, or combinations thereof; or enlarging the 10 concentration of the PDF, for instance to a PDF concentration of at least 0.1 mg of PDF per ml, more preferably of at least 1.0 mg/ml. The upper limit of the concentration of PDF is not critical if practical concentrations are being used. The use of stabilisation 15 measures is especially preferred when an easily oxidisable metal ion, e.g.  $Fe^{**}$  is present as a cofactor or an easily oxidisable substrate. If not, for instance in case  $Ni^{**}$  is present as a cofactor, the addition of a stabilisation agent appeared to be superfluous, as the 20 enzyme turned out to be very stable even without stabilisation agent.

In addition measures may be taken in order to enhance the stability of the enzyme, for instance the addition of stabilisation agents, for instance 25 catalase, tris-(2-carboxyethyl)phosphine, glucose oxidase, or combinations thereof; or enlarging the concentration of the PDF, for instance to a PDF concentration of at least 0.1 mg of PDF per ml, more preferably of least 1.0 mg/ml. The upper limit of the 30 concentration of PDF is not critical if practical concentrations are being used. The use of stabilisation measures is especially preferred when an easily

- 5 -

oxidisable metal ion, e.g.  $Fe^{++}$  is present as a cofactor or an easily oxidisable substrate. If not, for instance in case  $Ni^{++}$  is present as a cofactor the addition of a stabilisation agent appeared to be superfluous, as the 5 enzyme turned out to be very stable even without stabilisation agent.

Alternatively, genetically engineered mutants of PDF's may be used which have for instance enhanced activity or enantioselectivity in the (de)formylation 10 reaction. These mutants can be generated by a number of different approaches; for instance, by site-directed mutagenesis, site-specific random mutagenesis, regio-specific random mutagenesis, and completely random mutagenesis; the latter form of mutagenesis is better 15 known as directed evolution. General applicable methods to perform these different protein engineering approaches are well known to the skilled man. If a random approach will be applied, the mutagenesis cycle will need to be followed by selection of resistant and 20 active mutant(s), thereby leading to the identification of suitable mutants. To obtain PDF mutants also a combination of different protein engineering approaches and/or several rounds of random mutagenesis may be used.

25 The reaction conditions for the enzymatic deformylation or formylation according to the invention are not very critical and may depend on the substrates used. Any suitable solvent system which is inert towards the PDF may be applied; such solvents include 30 aqueous systems (solutions or slurries) or aqueous systems also containing a water-miscible organic

- 7 -

solvent which is inert under the reaction conditions. Aqueous systems, however, are preferred. Also the concentration of the *N*-formyl compound is not critical, and may be for instance in the range of about 0.1 to 5 1000 mM. It is not necessary that all of the *N*-formyl compound is dissolved; part of it may be present as a slurry. The concentration of the PDF likewise is not very critical, and usually will be at 0.001 to 100 % by weight of the formyl compound, e.g. at about 0.2 mM of 10 PDF. The pH for the reaction preferably is chosen in the range of 4.0 to 11.0, more preferably of 5.0 to 10.0. The optimum pH is determined by the stability of the  $\alpha$ -aminonitrile and/or the *N*-formyl- $\alpha$ -aminonitrile, and/or the stability and/or activity of the enzyme. The 15 person skilled in the art can easily determine the optimum pH-value. The temperature is not very critical, and suitably will be in the range of 10 to 50°C, e.g. at about 37°C, but for thermostable PDF enzymes higher temperatures may be applied.

20 In those cases wherein the absolute configuration of the (de)formylated enantiomer was determined, it appeared that the S-enantiomer was (de)formylated more rapidly than the R-enantiomer. The optical purity is given by the enantiomeric excess 25 (ee), the enantioselectivity of the enzyme is represented by E, and calculated as  $k_f/k_s$ , wherein  $k_f$  is defined as the rate constant of (de)formylation of the most rapidly (de)formylated enantiomer and  $k_s$  is defined as the rate constant of (de)formylation of the least 30 rapidly (de)formylated enantiomer.

Optionally a salt promoting hydrophobic

- 8 -

interactions is added to the reaction mixture, for instance a sulphate, phosphate, sulphite or acetate of ammonium, Rb, K, Na, Cs or Li. Most preferably ammonium sulphate or lithium sulphate is used.

5

The invention will further be elucidated by the following 3 examples, without being limited thereto.

10 Abbreviations:

TB medium: 12 g/l of Bacto-Tryptone, Difco; 24 g/l of yeast extract, Difco; 4 g/l of glycerole; 2.3 g/l of  $\text{KH}_2\text{PO}_4$ ; 12.5 g/l of  $\text{K}_2\text{HPO}_4$ ;

Hepes: N-2-hydroxyethylpiperazine-N'-2-ethane sulphuric acid;

15 AEBSF: 2-aminoethyl-p-benzene sulphonyl fluoride;

TCEP: tris-(2-carboxyethyl)-phosphine.

MOPS: 3-(N-morpholino) propane sulphonate

MES: 2-(N-morpholino) ethane sulphonate

20

Isolation of PDF(Fe)

For a detailed discussion of the methods used 25 reference is made to Groche et al., BBRC 246, 342-346 (1998).

PDF(Fe) was isolated from overproducing *E.coli* cells grown at 30°C in 1.6 l TB medium for 14-16 h. About 13 g (wet weight) cell paste were suspended in 30 26 ml buffer (20 mM Hepes/KOH, 100 mM KF, pH 7.7 supplemented with 10 µg/ml catalase from bovine liver (Boehringer Mannheim) and 1 mM AEBSF, disintegrated by

- 9 -

sonication (Branson B12, 20 min) at 0°C and centrifuged at 200.000g for 1 h. The clear supernatant (1.3 g of protein; according to biurete reaction) was mixed with 1.3 ml 10% (w/v) Polymyxin G-35 (BASF) adjusted to pH 7.7 and centrifuged at 40.000g for 10 min. The supernatant was applied to a 20 ml Met-Lys-Sepharose column that had been equilibrated with 20 mM Hepes/KOH, 100 mM KF, 0.2 mM TCEP, pH 7.7. After washing with 120 ml of 20 mM Hepes/KOH, 100 mM KF, 0.2 mM TCEP, pH 7.7, PDF(Fe) was eluted with 150 ml 20 mM Hepes/KOH, 100 mM KCl, 0.2 mM TCEP, pH 7.7. The protein containing fractions were concentrated by ultrafiltration using an Amicon PM10 membrane (yield: 140 mg protein, 1400 U/mg; determined according to Groche et al). After adjustment of the TCEP concentration to 1 mM and protein concentration to 40 mg/ml, the PDF(Fe) stock solution (40 mg/ml = 2 mM) was stored frozen at -60°C.

After thawing, the PDF(Fe) stock solution could be used directly in the deformylation experiments described below. If however solutions with lower PDF(Fe) concentrations were required for these deformylation experiments, the PDF stock solution was diluted further in 20 mM Hepes/KOH, pH 7.7, 100 mM KCl, 1 mg/ml bovine serum albumin, 10 µg/ml catalase solution.

25

HPLC-analysis

In all cases HPLC conditions had to be developed in which the two deformylated isomers were separated from each other and from the formylated isomers. To this end two different techniques were applied, i.e. method A and method B, as described

- 10 -

below.

From the concentrations of deformylated isomers in the samples after various reaction times, the (de)formylation rate constant ( $k_f$  and  $k_s$  in 5  $M^{-1}s^{-1}$ ) could be calculated for both enantiomers, as well as the respective ee values of the deformylated product. The enantioselectivity of the enzyme (E value) was calculated by taking the ratio  $k_f/k_s$  and is given, as well as the maximum ee value of the deformylated 10 product observed during the experiments, in the examples below.

Method A (without derivatization)

A Crownpak CR(+) column (4x150 mm) was used. Samples (5 15  $\mu$ l) withdrawn from the deformylation mixture were mixed with 95  $\mu$ l aqueous  $HClO_4$  (10 mM) to inactivate PDF( $Fe^{2+}$ ). Following a brief centrifugation, 20  $\mu$ l of the supernatant were applied to the Crownpak CR(+) column. For specific chromatographic conditions and 20 retention times see the examples II and III.

Method B (Precolumn derivatization with  
*o*-Phthaldialdehyde (OPA) and N-acetyl-L-cysteine:  
(NAC))

25 Samples (25  $\mu$ l) withdrawn from the deformylation mixture were mixed with 25  $\mu$ l aqueous  $HClO_4$  (100 mM) to inactivate PDF ( $Fe^{2+}$ ). Following a brief centrifugation, 40  $\mu$ l of the supernatant were added to 80  $\mu$ l 1 M aqueous  $H_2BO_3/NaOH$  pH 11, and subsequently 20  $\mu$ l OPA 30 reagent (consisting of OPA in  $H_2O/CH_3OH$  1:1 v/v with a

- 11 -

concentration as indicated in the example) was added, and 10 minutes later 20  $\mu$ l NAC reagent (consisting of NAC in  $\text{H}_2\text{O}/\text{CH}_3\text{OH}$  1:1 v/v with a concentration as indicated in the example) was added. After 5 min 5 derivatization was terminated by addition of 80  $\mu$ l (500 mM) aqueous  $\text{H}_3\text{PO}_4$ , and 20  $\mu$ l of the solution were instantaneously applied to a Nucleosil 120-5  $\text{C}_{18}$  column (250 x 4 mm). Temperature is ambient and detection is spectrophotometric using a wavelength of 257 nm and/or 10 340 nm; the used eluent is a mixture of 80 mol% aqueous 0.05 M  $\text{H}_3\text{PO}_4$  (brought at pH = 7.0 with 1 M NaOH) and 20 vol%  $\text{CH}_3\text{CN}$ .

Example I: Deformylation of N-formyl-valine

15 aminonitrile in the presence of  $\text{Li}_2\text{SO}_4$  at pH = 7.2.

The deformylation reaction of N-formyl-valine aminonitrile was performed in a 1.5 ml Eppendorf reaction test tube. The reaction mixture with a total volume of 200  $\mu$ l contained 100 mM aqueous MOPS/NaOH, 2 20  $\text{M Li}_2\text{SO}_4$  buffer pH 7.2, and 10 mM of N-formyl-valine aminonitrile. After thermal equilibration to 37°C the deformylation reaction was started by the addition of 50  $\mu$ M of PDF. At various reaction times samples of the reaction mixture were withdrawn in which the reaction 25 was stopped by addition of  $\text{HClO}_4$ .

HPLC-analysis was performed according to method B, with  $[\text{OPA}] = 16 \text{ mg/ml}$ , and  $[\text{NAC}] = 4 \text{ mg/ml}$ , retention times: 8.6 min (L-enantiomer), 10.2 min (D-enantiomer).

- 12 -

Results:

$E = 47.9$   
 $ee_{max} = 95.5$   
 $k_s = 0.62 \text{ M}^{-1}\text{s}^{-1}$   
5  $k_f = 29.7 \text{ M}^{-1}\text{s}^{-1}$

Example II: Deformylation of N-formyl-m-methoxy-phenylalanine aminonitrile without  $\text{Li}_2\text{SO}_4$  at pH 7.2

The deformylation reaction of N-formyl-m-methoxy-phenylalanine aminonitrile was performed as described in example I, with the exception that 100 mM MOPS/NaOH, 250 mM NaCl, 0.1 mg/ml catalase buffer pH 7.2 was used instead of 100 mM MOPS/NaOH, 2 M  $\text{Li}_2\text{SO}_4$  buffer pH 7.2. Furthermore, 7.2 mM of N-formyl-m-methoxy-phenylalanine aminonitrile and 2.5  $\mu\text{M}$  of PDF were used.

HPLC-analysis was performed according to method A

Eluent: 90 vol% 10 mM aqueous  $\text{HClO}_4$ /10 vol%  $\text{CH}_3\text{OH}$

20 Flow rate: 0.8 ml/min, temperature: 5° C, detection: 210 nm,

retention times:

Deformylated enantiomer(s): 23.8 min.

30.7 min.

25 N-formyl aminonitrile: 52.0 min.

Results:

$E = 685$   
 $ee_{max} = 99.0$   
30  $k_f = 1370 \text{ M}^{-1}\text{s}^{-1}$   
 $k_s = 2 \text{ M}^{-1}\text{s}^{-1}$

- 13 -

Example III: Deformylation of N-formyl-phenylalanine aminonitrile without  $\text{Li}_2\text{SO}_4$  addition at pH 6.2.

5 The deformylation reaction of *N*-formyl-phenylalanine aminonitrile was performed as described in example I, with the exception that 100 mM MES/NaOH buffer pH 6.2 was used instead of 100 mM MOPS/NaOH, 2 M  $\text{Li}_2\text{SO}_4$  buffer pH 7.2. Furthermore, 7.5 mM of *N*-formyl-phenylalanine aminonitrile and 20  $\mu\text{M}$  of PDF were used.

10

HPLC-analysis was performed according to method A

Eluent: 90 vol% 10 mM aqueous  $\text{HClO}_4$ /10 vol%  $\text{CH}_3\text{OH}$

Flow rate: 0.8 ml/min, temperature: 5° C, detection: 210 nm,

15 retention time:

deformylated aminonitrile: 11.8 min

15.1 min

*N*-formyl aminonitrile: 28.6 min.

20 Results:

$E = 880$

$ee_{\text{max}} = 98.8$

$k_f = 880$

$k_s = 1$

- 14 -

CLAIMS

1. Process for the preparation of an  $\alpha$ -aminonitrile with enhanced optical purity wherein a mixture of the enantiomers of a chiral N-formyl  $\alpha$ -aminonitrile is brought into contact with an acylase, whereby one of the enantiomers of the N-formylaminonitrile is selectively deformylated into the unprotected corresponding  $\alpha$ -aminonitrile.
5. Process for the preparation of an  $\alpha$ -aminonitrile with enhanced optical purity wherein a mixture of the enantiomers of a chiral (unprotected)  $\alpha$ -aminonitrile is subjected to a formylation reaction in the presence of an acylase and a formylating agent whereby one of the enantiomers is selectively converted in N-formyl  $\alpha$ -aminonitrile.
10. Process according to claim 2 wherein formic acid, a formic acid amide or a formic acid ester is used as a formylating agent.
15. Process according to any of claims 1-3, wherein a peptide deformylase with a bivalent metal ion wherein the metal is chosen from group 5-11 of the periodic system, is used as acylase.
20. Process according to any of claims 1-4, wherein the peptide deformylase is chosen from the class EC 3.5.2.27 or EC 3.5.1.31.
25. Process according to any of claims 1-5, wherein the peptide deformylase contains the sequences of (I) HEXXH, (ii) EGCLS and (iii) GXGXAAXQ.
30. Process according to any of claims 4-6, wherein the peptide deformylase is from *Escherichia coli*.
35. Process according to any of claims 1-7, wherein the peptide deformylase is from *Escherichia coli*.
40. Process according to any of claims 1-8, wherein the peptide deformylase is from *Escherichia coli*.
45. Process according to any of claims 1-9, wherein the peptide deformylase is from *Escherichia coli*.
50. Process according to any of claims 1-10, wherein the peptide deformylase is from *Escherichia coli*.
55. Process according to any of claims 1-11, wherein the peptide deformylase is from *Escherichia coli*.
60. Process according to any of claims 1-12, wherein the peptide deformylase is from *Escherichia coli*.
65. Process according to any of claims 1-13, wherein the peptide deformylase is from *Escherichia coli*.
70. Process according to any of claims 1-14, wherein the peptide deformylase is from *Escherichia coli*.
75. Process according to any of claims 1-15, wherein the peptide deformylase is from *Escherichia coli*.
80. Process according to any of claims 1-16, wherein the peptide deformylase is from *Escherichia coli*.
85. Process according to any of claims 1-17, wherein the peptide deformylase is from *Escherichia coli*.
90. Process according to any of claims 1-18, wherein the peptide deformylase is from *Escherichia coli*.
95. Process according to any of claims 1-19, wherein the peptide deformylase is from *Escherichia coli*.

- 15 -

8. Process according to any of claims 4-7, wherein the bivalent metal is chosen from the group of Fe, Ni, Mn and Co.
9. Process according to claim 8, wherein the bivalent metal is Ni.
- 5 10. Process according to any of claims 1-8, wherein in addition a stabilisation agent is added.
11. Process according to claim 10 wherein the stabilisation agent is catalase.
- 10 12. Process according to claim 10 or 11 wherein the bivalent metal is Fe.

ABSTRACT

Process for the preparation of an  $\alpha$ -aminonitrile with enhanced optical purity wherein a mixture of the enantiomers of a chiral N-formyl  $\alpha$ -aminonitrile is brought into contact with an acylase, whereby one of the enantiomers of the N-formylaminonitrile is selectively deformylated into the unprotected corresponding  $\alpha$ -aminonitrile, and a process for the preparation of an  $\alpha$ -aminonitrile with enhanced optical purity wherein a mixture of the enantiomers of a chiral (unprotected)  $\alpha$ -aminonitrile is subjected to a formylation reaction in the presence of an acylase and a formylating agent whereby one of the enantiomers is selectively converted in N-formyl  $\alpha$ -aminonitrile. Preferably a peptide deformylase with a bivalent metal ion wherein the metal is chosen from group 5-11 of the periodic system, is used as acylase, for instance a peptide deformylase chosen from the class EC 3.5.2.27 or EC 3.5.1.31. Such peptide deformylases often contain the sequences of (I) HEXXH, (ii) EGCLS and (iii) GXGXAAQ. The bivalent metal is preferably chosen from the group of Fe, Ni, Mn and Co, in particular Ni or Fe.